Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial

    Circulation Date published:

  • Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials

    Diabetes, Obesity and Metabolism Date published:

  • Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

    American Journal of Kidney Diseases Date published:

  • Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

    Journal of the American Heart Association Date published:

  • Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials

    Kidney International Date published:

  • A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine Date published:

  • Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

    BMJ Open Diabetes Research & Care Date published:

  • #3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D

    Nephrology Dialysis Transplantation Date published:

  • #4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY

    Nephrology Dialysis Transplantation Date published:

  • Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

    Diabetes, Obesity and Metabolism Date published:

  • The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

    Diabetes, Obesity and Metabolism Date published:

  • Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

    Kidney International Reports Date published:

  • IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

    Kidney International Reports Date published:

  • Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

    The Lancet Date published:

  • Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published: